MWNA
CYTK icon

Marshall Wace North America’s Cytokinetics CYTK Stock Holding History

Marshall Wace North America’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.65M Sell
46,260
-1,100,242
-96% -$32.4M 0.01% 778
2021
Q2 		$22.7M Sell
1,146,502
-1,553,621
-58% -$36.5M 0.1% 229
2021
Q1 		$62.8M Buy
2,700,123
+632,255
+31% +$13.5M 0.26% 86
2020
Q4 		$43M Buy
+2,067,868
New +$37.8M 0.19% 132
2018
Q4 		– Sell
-131,062
Closed -$1.29M – 1504
2018
Q3 		$1.29M Buy
+131,062
New +$1.05M 0.01% 567

Other funds holding CYTK

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return